Amplifon brakes after Australian Cochlear's profit warning
Although the impact on European competitors will be 'limited' given 'their low exposure to cochlear implants', investors prefer to take profits on industry stocks
Le ultime da Radiocor
Borsa: fiammata tech non basta, Milano in rosso (-0,5%) con tensioni Hormuz
***Vertice Ue: von der Leyen, per ora no stop regole bilancio ma 'stiamo in allerta'
Usa: indice fiducia consumatori U.Michigan aprile scende a 49,8
(Il Sole 24 Ore Radiocor) - Sales on Amplifon at the Italian Stock Exchange, after the profit warning from Australian Cochlear, a company active in the production of cochlear implants. The hearing aid company's share price dropped almost three points in a cautious Ftse Mib.
In detail, Cochlear issued a profit warning and significantly reduced its adjusted net profit guidance for the financial year 2026 (ending 30 June). As Intermonte recalls, the company now expects adjusted net profit to be in the range of A$290 to A$330 million, down from around A$435 to A$460 million previously (about -30%), with consensus at A$312 million.
Loading...
"The revision," the experts write, "reflects weaker demand in developed markets and discontinuities in emerging markets, compounded by hospital operating constraints and macro/geopolitical factors. Sydney-listed Cochlear's stock lost more than 40 per cent. Although, according to Intermonte's analysts, the impact on European competitors will be "limited" given "their low exposure to cochlear implants", investors prefer to take profits on stocks in the sector: in addition to Amplifon, Gn Store Nord (-1.7%), Demant in Copenhagen (-2.1%) and Sonova in Zurich (-4.3%) are down.
Copyright reserved ©
Brand connect
Loading...
